Universal Beteiligungs und Servicegesellschaft mbH Purchases New Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH purchased 1,969 shares of Madrigal Pharmaceuticals, Inc. valued at approximately $652,000 during the first quarter, marking a new investment in the biopharmaceutical company.
• Madrigal Pharmaceuticals reported quarterly earnings of ($3.32) EPS, beating analysts' estimates, and generated $137.25 million in revenue, exceeding expectations by a significant margin.
• Recent upgrades from various research firms raised the price target for Madrigal Pharmaceuticals, with UBS Group increasing it to $458 and maintaining a "buy" rating, reflecting positive analyst sentiment towards the stock.

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,969 shares of the biopharmaceutical company's stock, valued at approximately $652,000.

A number of other large investors have also made changes to their positions in MDGL. Mutual of America Capital Management LLC lifted its stake in Madrigal Pharmaceuticals by 0.3% in the 1st quarter. Mutual of America Capital Management LLC now owns 11,263 shares of the biopharmaceutical company's stock worth $3,731,000 after purchasing an additional 31 shares in the last quarter. Pitcairn Co. lifted its position in Madrigal Pharmaceuticals by 3.2% during the fourth quarter. Pitcairn Co. now owns 1,060 shares of the biopharmaceutical company's stock valued at $327,000 after purchasing an additional 33 shares during the last quarter. First Horizon Advisors Inc. lifted its position in Madrigal Pharmaceuticals by 38.9% during the first quarter. First Horizon Advisors Inc. now owns 157 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 44 shares during the last quarter. GAMMA Investing LLC lifted its position in Madrigal Pharmaceuticals by 131.4% during the first quarter. GAMMA Investing LLC now owns 118 shares of the biopharmaceutical company's stock valued at $39,000 after purchasing an additional 67 shares during the last quarter. Finally, Verity Asset Management Inc. lifted its position in Madrigal Pharmaceuticals by 4.7% during the first quarter. Verity Asset Management Inc. now owns 1,560 shares of the biopharmaceutical company's stock valued at $517,000 after purchasing an additional 70 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on MDGL. Wall Street Zen upgraded shares of Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th. B. Riley reaffirmed a "buy" rating and issued a $460.00 price objective (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd. Canaccord Genuity Group upped their price objective on Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. UBS Group raised their price objective on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. Finally, JMP Securities restated a "market outperform" rating and set a $443.00 price objective on shares of Madrigal Pharmaceuticals in a report on Thursday, April 24th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $420.63.

Insider Buying and Selling

In related news, Director Paul A. Friedman sold 1,400 shares of the company's stock in a transaction that occurred on Friday, July 18th. The stock was sold at an average price of $350.03, for a total value of $490,042.00. Following the sale, the director owned 187,164 shares in the company, valued at $65,513,014.92. This represents a 0.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Rebecca Taub sold 1,000 shares of the company's stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $350.00, for a total value of $350,000.00. Following the completion of the sale, the director owned 461,044 shares in the company, valued at approximately $161,365,400. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,377 shares of company stock valued at $21,316,969 over the last quarter. 21.50% of the stock is owned by company insiders.

Madrigal Pharmaceuticals Stock Down 0.7%

NASDAQ:MDGL traded down $2.33 during midday trading on Wednesday, reaching $336.59. 183,409 shares of the stock traded hands, compared to its average volume of 375,140. Madrigal Pharmaceuticals, Inc. has a 12-month low of $200.63 and a 12-month high of $377.46. The business has a 50-day moving average of $297.49 and a two-hundred day moving average of $312.32. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.58 and a current ratio of 5.91. The stock has a market capitalization of $7.47 billion, a PE ratio of -18.59 and a beta of -1.02.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) EPS for the quarter, beating analysts' consensus estimates of ($3.48) by $1.58. Madrigal Pharmaceuticals had a negative net margin of 123.38% and a negative return on equity of 50.54%. The company had revenue of $212.80 million during the quarter, compared to analysts' expectations of $158.94 million. During the same quarter in the prior year, the company posted ($7.10) earnings per share. Madrigal Pharmaceuticals's revenue for the quarter was up 1357.5% compared to the same quarter last year. On average, equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.